Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + temozolomide
- Development stage
- Unknown
- Lead developer
- Cancer Research UK
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of three anticancer drugs: paclitaxel, carboplatin, and temozolomide. The regimen has been studied in phase I and II clinical trials for patients with advanced solid tumors, particularly showing activity in melanoma and small cell lung cancer. In the standard protocol, paclitaxel (175 mg/m²) and carboplatin (AUC 5) are administered on day 1, followed by temozolomide (75-125 mg/m²/day) on days 2-6 of a 28-day cycle.
- Other names
- CP-T regimenCarboplatin/Paclitaxel/Temozolomide combination
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on paclitaxel + carboplatin + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + temozolomide.